Table 1

Baseline characteristics of the study participants

Control participants N=87HIV-positive participants N=73p Value
Male (N)8773
Smoking n (%)21 (24)22 (30)0.36
Diabetes n (%)24 (28)9 (13)0.02
Triglycerides (mmol/L)1.8±1.52.5±1.70.04
Total cholesterol (mmol/L)4.7±1.35±1.30.14
LDL cholesterol (mmol/L)2.6±1.52.9±10.36
HDL cholesterol (mmol/L)1.3±0.31.1±0.30.22
BMI (kg/m2)29.0±7.424.8±4.3<0.001
STEMI n (%)13 (15)8 (11)0.48
NSTEMI n (%)41 (47)30 (41)0.48
High-risk chest pain n (%)33 (38)35 (48)0.20
Hypertension treatment n (%)30 (35)46 (63)<0.001
Statin usage n (%)29 (33)47 (64)<0.001
Duration of HIV diagnosis (years)NA11.02±4NA
Viral load <50 (%)NA89NA
CD4 countNA510±220NA
CRP (mg/L)*3.7±3.613.4±15.4<0.001
PI n (%)NA(51) 70NA
NRTI n (%)NA(62) 85NA
NNRTI n (%)NA(68) 82NA
Abacavir usage n (%)†NA21 (29)NA
  • Continuous data are mean±SD unless otherwise indicated.

  • *As measured on the day of admission.

  • †As documented as part of ART regime on the day of admission.

  • BMI, body mass index; CRP, C reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NA, not available; NNRTI, non-nucleoside reverse transcription inhibitor; NRTI, nucleoside reverse transcription inhibitor; NSTEMI, non-ST elevation myocardial infarction; PI, protease inhibitor; STEMI, ST elevation myocardial infarction; UAP, unstable angina pectoris.